CANCER & COVID-19 : an IPC – Inserm research project funded by the ARC foundation for its high impact

Published on

The project from Institut Paoli-Calmettes Institute and Inserm is one of the 5 “high impact flash research” projects selected by the ARC foundation for funding, with the aim to to speed up research and better protect cancer patients in the event of future epidemics.

” Our goal is to develop immunotherapies targeting mechanisms common to certain cancers and to Covid-19. This project is led by Thomas Miller – an American colleague who joined the team thanks to funding from the NIH (National Institutes of Health, USA) and which fits perfectly the focus of our team “- Yves Collette, Director Inserm, is co-leader of a research team at the Paoli-Calmettes Institute and at the Center for Cancer Research of Marseille.

The team works to identify proteins that contribute to oncogenesis, and then to discover pharmacological molecules targeting interactions between these proteins. Their goal is to ensure the transfer of these therapeutic targets to pre-clinical and clinical development programs in oncology.

The team is entitled “Structural Biology and Integrated Chemistry-Biology”, and it has 23 members, including 6 who will participate in this innovative project. This project will be part of the R&D platform of the Paoli-Calmettes Institute, in collaboration with virologists, immunologists from Marseille as well as CisBio (PerkinElmer).

ARC press release